The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development ... are urged to get Covid-19 shots each fall.

The Food and Drug Administration announced Tuesday it has picked a new head of its center charged with vaccine approvals ... speed up the development of vaccines during the COVID-19 pandemic.

A landmark study by scientists at the University of Oxford, has unveiled crucial insights into the way that COVID-19 vaccines mitigate severe illness in those who have been vaccinated.

Invivyd, Inc. has submitted a Citizen Petition to the FDA advocating for a new approach to the development of COVID-19 vaccines and monoclonal antibodies (mAbs) to restore public trust in health ...

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...

Rudman Spergel, MD, director of clinical development at Moderna ... the technology to create one of the world’s first COVID-19 vaccines. In 2023, the company announced results from a phase ...

Trump halted biological research funding to adversaries such as China and Iran because of concerns COVID-19 originated in a ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...